Factors Affecting the Price of Rubraca

Rubraca (rucaparib), a PARP inhibitor, has a price shaped by key factors. High R&D costs, from developing this drug for BRCA-mutated cancers (e.g., ovarian, breast) and extensive clinical trials, drive pricing. 

Factors Affecting the Price of Rubraca

Clovis Oncology’s patent protection ensures market exclusivity, allowing premium rates without generic competition. Production complexities, including specialized manufacturing for its formulations, add to costs. 

Market demand for targeted therapies in homologous recombination-deficient tumors and regional healthcare policies (e.g., insurance coverage) further influence the final price patients pay.